OPTIMIZED BY EVOLUTION
Wugen is developing off-the-shelf cellular therapies for cancer
Our cell therapy products originate from healthy donors and are further manipulated in order to enhance their function to eliminate cancer cells. Our NK cell and CAR-T immuno-oncology therapies address the needs of patients with solid tumors, acute myeloid leukemia (AML) and T-cell malignancies.
At Wugen, we are developing off-the-shelf: